The downgrade from Outperform to Neutral by a reputable analyst like Eric Coldwell at Baird indicates a shift in sentiment towards Medpace Holdings. The lowered price target from $413 to $349 suggests expectations of lower future performance, likely leading to a negative short-term impact on the stock price.